by heshamhamed | Jan 31, 2025 | News
Adoram’s co-CEOs, David Pejoski and Hesham Hamed, served as faculty members for the Executive Education program on Biobusiness in Lugano, Switzerland. They presented Adoram as a business case in the advanced BioEntrepreneurship program at Università della...
by heshamhamed | Jan 31, 2025 | News
Adoram was selected as one of the 5 Swiss startups to attend a full week in Japan. Co-CEO Dr. David Pejoski represented Adoram during the Japanese roadshow, which included attendance to BioJapan Yokohama, pitching to investors at events at SwissNex in Osaka and the...
by heshamhamed | Jan 31, 2025 | News
Adoram Therapeutics was selected to take part in a roadshow in Boston, USA, alongside nine other selected Swiss startups, providing a comprehensive deep dive into the east coast US biotech scene, with introductions to world class venture capital firms, local...
by heshamhamed | Jan 31, 2025 | News
Adoram was chosen to present to an expert panel comprising various regional stakeholders. Dr. Hesham Hamed, our Chief Scientific Officer, showcased Adoram’s business model and unique approach of utilizing allosteric small molecules to address unmet medical...
by heshamhamed | Feb 23, 2024 | News
Adoram management presented before an expert panel for the stage I venture kick startup competition. The concept of Leveraging allosteric biochemistry for patients was found convincing by the jury and was granted 10K CHF. For further details, please refer to the...
by heshamhamed | Feb 23, 2024 | News
We are heading to Sachs’ 16th Annual European Life Sciences CEO forum to discuss the latest data package generated by Adoram Therapeutics. Not only do we show superior efficacy, but more importantly improved safety compared to competitors thanks to our unique MoA....
